Skip to content

Axogen AXGN Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

LeMaitre Vascular logo
LeMaitre VascularLMAT

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's amortization expense related to capitalized debt issuance costs?
Axogen (AXGN) reported amortization expense related to capitalized debt issuance costs of $68K in Q1 2026.
How has Axogen's amortization expense related to capitalized debt issuance costs changed year-over-year?
Axogen's amortization expense related to capitalized debt issuance costs decreased by 69.1% year-over-year, from $220K to $68K.
What is the long-term trend for Axogen's amortization expense related to capitalized debt issuance costs?
Over 4 years (2021 to 2025), Axogen's amortization expense related to capitalized debt issuance costs has grown at a 0.7% compound annual growth rate (CAGR), from $869K to $892K.